PharmaLegacy Laboratories Seminar-Accelerating Preclinical Drug Discovery with Animal Models of Humanized Mice and Non-Human Primates
This seminar will present you the animal models PharmaLegacy Laboratories have developed for your preclinical drug discovery in the areas of immuno-oncology/oncology, inflammation/autoimmune diseases, bone/orthopedics and metabolic and liver diseases. Find out how PharmaLegacy can help you to evaluate the efficacy of novel drug candidates by using these over 300 validated animal disease models.
10:30 am – 11:00 am: Introduction of PharmaLegacy Laboratories and General Business Overview
11:00 am – 11:45 am: Translational Immuno-Oncology: Use of Humanized Mouse and Human Tissue Based Models in Preclinical Research
11:45 am – 12:30 pm: Lunch & Networking
12:30 pm – 1:00 pm: Non-Human Primate (NHP) Platforms for Inflammation/Autoimmune Diseases, Bone/Orthopedics, Respiratory Disease and Pharmacokinetics Profiling Assay
1:00 pm – 1:30 pm Animal models of Inflammation/Autoimmune Diseases
1:30 pm – 2:00 pm Free Discussion & Animal Disease Models Upon Request
About PharmaLegacy Laboratories
PharmaLegacy Laboratories (PL), is a leading specialty pharmacology Contract Research Organization located in Shanghai, Zhangjiang High-Tech Park, China. PL provides preclinical pharmacology services in Immuno-Oncology (Oncology), Inflammation/Auto-Immune diseases, Bone/Orthopedics and Liver/Metabolic diseases, as well as Non-Human Primates (NHP) platform for biologics testing. Our core competency stems from our pioneering work in running clinically predictive animal disease models to test drug candidates and medical devices for pharmacological effects and biocompatible repairs.
Our animal species for disease models ranged from rodents, rabbits, dogs to NHP. The vivarium is fully accredited by AAALAC. In addition to efficacy studies, we also provide services in PK/PD, ADA, molecular pharmacology and non-GLP toxicology. Overall we provide one-stop shopping of preclinical pharmacological service from early proof of concept of therapeutics to fulfilment of regulatory requirements.